logo-altasciences

EN - Main navigation

  • Proactive Drug Development
  • Solutions
  • Compare Us
  • Facilities
  • About Us
  • Resource Center
  • Careers
  • News & Events
  • Contact Us
  • Participate in a study
Français
  • Home
  • Current: Kenton H. Zavitz

KENTON H. ZAVITZ

Share this page

Kenton H. Zavitz, PhD
Director of Clinical Affairs, Cambridge Cognition Ltd

Dr. Zavitz has over 17 years of biotechnology and pharmaceutical experience with involvement in all aspects of the industry from drug discovery and clinical development through to pre-commercialization. Prior to joining Cambridge Cognition, he served as Chief Scientific Officer for New Mexico-based biotech Zocere Inc., where he worked on developing a neuroprotectant drug designed to combat brain injury resulting from stroke. He currently serves on the Scientific Advisory Board for Exonate Limited, a start-up founded in 2013 at the University of Nottingham. From 1998 to 2012, Dr. Zavitz worked at Myriad Pharmaceuticals, Inc. in Salt Lake City and served in a variety of roles, including Senior Director of Clinical Affairs, Chief Scientist of the tarenflurbil clinical development program (an investigational drug for the treatment of Alzheimer’s disease, developed through Phase 3), Director of Neurodegeneration Therapeutics Discovery and Director of Strategic In-licensing and Scientific Evaluation. Dr. Zavitz received his PhD in Biochemistry and Molecular Biology from The Sloan-Kettering Division of the Weill Cornell Graduate School of Medical Sciences in New York City. He was a Postdoctoral Fellow at the UCLA School of Medicine, and was awarded fellowships from the Leukemia Society of America and the Jane Coffin Childs Memorial Fund for Medical Research.

« Back to Agenda         View the abstract "Cognitive assessments for neuroscience drugs in early phase studies" »

Sign up for exclusive content

Join our list of 30,000+ VIP members and have access to our exclusive content.

Stay connected

  • linkedin
  • youtube

Footer

    • Solutions

      • Preclinical Services
      • Clinical Services
      • Manufacturing and Analytical Services
      • Bioanalytical Services
      • Research Support Services
      • Development Programs
    • News & Events

      • Altasciences Events
      • Press Releases
      • Altasciences in the News
      • Press Kit
    • Resource Center

      • The Altascientist
      • Webinars/Podcasts
      • Newsletters
      • Scientific Publications
      • Blog
      • Videos
    • Study Types

      • Preclinical
      • Lead Optimization
      • Pharmacology
      • Pharmacokinetics/​Pharmacodynamics
      • Acute Toxicology
      • Dose Range Finding​/​Maximum Tolerated Dose
      • Repeated Dose Toxicity
      • Safety Pharmacology
      • Sub-Chronic/Chronic, Repeated Dose Toxicity
      • Clinical
      • First in Human
      • Proof of Concept
      • Bioavailability/Bioequivalence
      • Pharmacokinetics in Special Populations
      • Human Abuse Potential
      • Driving Simulation
      • Drug-Drug Interaction
      • QT Assessment
      • Renal and Hepatic Impaired
      • Imaging
      • Biologics​/​Biosimilars
    • Therapeutic Areas

      • Cardiology
      • Dermatology
      • Gastroenterology
      • Hematology
      • Immunology
      • Infectious Diseases
      • Metabolism and Endocrinology
      • Neurology
      • Oncology
      • Ophthalmology
      • Orthopedics
      • Psychiatry
      • Respirology
      • Rheumatology
      • Substance Abuse
      • Urology
      • Women’s Health
    • About us

      • History
      • Our Origins
      • Awards
      • Testimonials
    • Careers

    • Contact Us

    • Locations

    • Stay connected

      • Facebook
      • Youtube

2025 © Altasciences. All Rights Reserved.

Cookie Policy | Privacy Policy

Have a question?

I'd be happy to help.

Captcha is required.